Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - VIVUS INC | vvus-20160630x10q.htm |
| EX-32 - EX-32 - VIVUS INC | vvus-20160630xex32.htm |
| EX-31.2 - EX-31.2 - VIVUS INC | vvus-20160630ex31224466c.htm |
| EX-31.1 - EX-31.1 - VIVUS INC | vvus-20160630ex3119b5fa6.htm |
June 30, 2016
Via email:
John Slebir
General Counsel
VIVUS, Inc.
351 E. Evelyn Ave.
Mountain View, CA 94041
Re:Termination Notice
Dear Mr. Slebir:
This is to confirm our understanding that the date of the termination of the License and Commercialization Agreement between Vivus, Inc. and Auxilium Pharmaceuticals, Inc., an Endo international company, dated October 10, 2013 (the “License Agreement”), is hereby extended to August 31, 2016.
Sincerely,
AUXILIUM PHARMACEUTICALS, INC.ENDO VENTURES LIMITED
/s/ Deanna Voss/s/ Robert Cobuzzi
Deanna VossRobert Cobuzzi
Assistant SecretaryDirector
Accepted and agreed:
VIVUS, INC.
/s/ Mark Oki